Full Breakdown
Phase I Trial Shows Safety and Durable Immune Responses for KRAS-Targeted Pancreatic Cancer Vaccine
7/17/2026, 3:51:07 AM
Background & Context
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a five-year survival rate below 10 %. About 10 % of cases arise from hereditary predisposition, often linked to pathogenic mutations in cancer-susceptibility genes. PDAC typically evolves from precursor lesions such as pancreatic intraepithelial neoplasia, intrapapillary mucinous neoplasms, or small cysts that can be monitored by imaging but are frequently microscopic and undetectable. Current management for high-risk individuals relies on surveillance and, when warranted, surgical resection—a strategy that still carries recurrence rates up to 80 %.
Key Figures & Groups
- Elizabeth M. Jaffee, MD, FAACR – Deputy director, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins; co-senior author of the study.
- Neeha Zaidi, MD – Associate professor of oncology, Johns Hopkins; co-senior author and principal investigator.
- Michael G. Goggins, MD – Professor of pathology, medicine, and oncology at Johns Hopkins; senior author.
- mKRAS-VAX – An off-the-shelf synthetic long-peptide vaccine targeting the six most common KRAS mutations found in PDAC and its precursors.
- Funding agencies include the National Cancer Institute, the Lustgarten Foundation, and a Stand Up To Cancer-Lustgarten Foundation Translational Cancer Research Grant.
Core Trial Findings (Phase I)
The investigators enrolled 20 participants with hereditary risk and radiographic pancreatic lesions (typically small cysts) between April 2022 and February 2026. Participants received subcutaneous injections of mKRAS-VAX on weeks 1, 3, 5 (prime) and week 13 (boost). Blood sampling tracked immune responses for a median of 16.5 months (follow-up up to two years).
- Safety: Only mild injection-site reactions and transient flu-like symptoms were reported; no serious adverse events occurred.
- Immune activation: Mutant-KRAS-specific effector and central-memory T-cell responses were detected in 90 % of participants (18 of 20), with a median 18.2-fold increase in T-cell frequency. Responses persisted for up to two years.
- Clinical observations: No participant developed pancreatic cancer during follow-up. Cyst reduction or resolution occurred in 37.5 % of vaccinated individuals versus 6.8 % in a comparable unvaccinated cohort.
Data & Statistics
| Metric | Result |
|---|---|
| Participants | 20 (high-risk, hereditary + cyst) |
| KRAS-specific T-cell response | 90 % (18/20) |
| Median increase in T-cell frequency | 18.2 × |
| Median follow-up | 16.5 months |
| Cyst reduction/resolution | 37.5 % (vaccinated) vs 6.8 % (unvaccinated) |
| Cancer incidence | 0 % (vaccinated) |
Why It Matters
KRAS mutations drive >90 % of PDACs, making them a logical preventive target. Demonstrating that a KRAS-directed vaccine can safely elicit durable, systemic T-cell immunity in humans establishes a proof-of-concept for cancer interception—a strategy that could shift focus from treatment to prevention for high-risk populations.
Official Statements & Responses
- The investigators emphasized that the trial was designed to assess safety and immune durability, not clinical efficacy.
- Ongoing studies will examine vaccine-induced T-cell infiltration within precancerous tissue, addressing the limitation of peripheral-blood-only analyses.
- Funding disclosures note multiple industry advisory roles and equity interests for Dr. Jaffee and Dr. Zaidi, though no conflicts were reported for Dr. Goggins.
Criticism & Limitations
- The sample size (n = 20) is small, limiting statistical power and generalizability.
- The trial was not randomized nor powered to determine whether observed cyst regression is attributable to the vaccine.
- Peripheral blood monitoring cannot confirm that T-cells reach pancreatic lesions; tissue-based endpoints are pending.
Conflicting Reports & Gaps
All sources agree on safety and immune activation; however, the absence of cancer events could reflect the short follow-up rather than definitive prevention. No data are available on long-term cancer incidence or on vaccine efficacy in larger, diverse cohorts.
Verbatim Quotes
- “If there is a high enough concern for transformation to cancer or if early cancer is detected, the current standard of care is surgical resection. However, the chances of recurrence are up to 80%, and many precursor lesions to pancreatic cancer are microscopic and thus undetectable by imaging.” — Neeha Zaidi, MD
- “This long-lasting response is particularly noteworthy when assessing for possible interception of cancer, which requires long-lasting immunity,” — Neeha Zaidi
- “Overall, this study represents the first proof of concept for the use of vaccines for interception of pancreatic cancer in human patients,” — Elizabeth Jaffee, MD
- “This is just the beginning, but the findings suggest that the immune system is getting activated,” — Elizabeth Jaffee, MD
- “In addition, the vaccine was safe and well tolerated, supporting its use in larger cancer interception studies.” — Neeha Zaidi, MD
What’s Next
A currently enrolling trial will collect pancreatic tissue samples to determine whether vaccine-elicited T-cells infiltrate precancerous lesions, providing a direct measure of on-target activity. Results from larger, possibly randomized studies will be needed to establish clinical efficacy.
